Research
Lynch Syndrome, the Most Common of the Rarest
Next month is Lynch Syndrome Day, also known as Hereditary Non-Polyposis Colorectal Cancer, so we will remind people that those who have Lynch synd...
ASCO GI Highlights – Positive Data in Earlier Stage HCC Results
The American Society for Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, USA 18-20 January this year. At ...
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer
GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants in...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial
Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...
RWE Research in mCRC
In a recent article published in the Future Oncology, Patient Advocates and DiCE CEO Zorana Maravic explored and enhanced the understanding of the ...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
